动脉溶栓术联用尤瑞克林对急性后循环脑梗死患者预后的影响

Influence of arterial thrombolysis combined with urinary kallidinogenase on the prognosis of patients with acute posterior circulation cerebral infarction

  • 摘要: 目的:观察动脉溶栓术联用尤瑞克林对急性后循环脑梗死患者预后的影响。方法将40例急性后循环脑梗死且行动脉溶栓的患者随机分为治疗组1和治疗组2,每组20例。治疗组1给予动脉溶栓治疗,继后联用尤瑞克林治疗14 d;治疗组2仅给予动脉溶栓治疗。同时选择20例拒绝溶栓治疗的患者作为对照组,行常规内科保守治疗。治疗14 d 后,比较3组临床疗效、美国国立卫生院神经功能缺损(NIHSS)评分和日常生活能力(ADL)评分,并观察不良反应发生情况。结果治疗组临床好转率明显优于对照组,且病死率明显低于对照组,差异有统计学意义。治疗后,治疗组1和2 NIHSS 和ADL 评分均较对照组明显改善,其中治疗组1 NIHSS 改善程度显著优于治疗组2,且 ADL 略优于治疗组2。治疗组不良反应发生率较高,但致死率无增加。结论动脉溶栓联合尤瑞克林能显著改善急性后循环脑梗死患者的预后,在不增加不良反应的情况下,其疗效优于单用动脉溶栓治疗。

     

    Abstract: Objective To explore the influence of arterial thrombolysis combined with uri-nary kallidinogenase on the prognosis of patients with acute posterior circulation cerebral infarction (PCCI).Methods 40 patients with acute PCCI and arterial thrombolysis were randomly divided into treatment group 1 and 2,20 cases in each group.Both groups were treated with arterial throm-bolysis,whereas treatment group 1 was given urinary kallidinogenase for 14 days after that.Mean-while,20 patients refusing to undergo arterial thrombolysis were selected as control group and were given routine conservative treatment.14 days after treatment,the clinical efficacy,NIHSS score and ADL score as well as adverse reactions were compared among 3 groups.Results The clinical improvement rates in treatment group were obviously higher than control group,and mortality was significantly lower than control group.After treatment,NIHSS and ADL scores in treatment group 1 and 2 were improved significantly by comparison with control group,and the improved degrees of NIHSS and ADL in treatment group 1 were notably and slightly greater than treatment group 2. Conclusion Arterial thrombolysis combined with urinary kallidinogenase can significantly amelio-rate the prognosis of patients with acute PCCI and shows a better efficacy than single arterial throm-bolysis without increasing the incidence rate of the adverse reactions.

     

/

返回文章
返回